The DOI matches its Crossref record.
Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance
Open accessAbstract
Purpose: Active surveillance is now considered a viable treatment option for men with low-risk prostate cancer. However, little is known regarding changes in Gleason grade on serial biopsies over an extended period of time. Patients and Methods: Men diagnosed with prostate cancer between 1998 and 2009 who elected active surveillance as initial treatment, with 6 or more months of follow-up and a minimum of six cores at biopsy, were included in analysis. Upgrading and downgrading were defined as an increase or decrease in primary or secondary Gleason score. Means and frequency tables were used to describe patient characteristics, and treatment-free survival rates were determined by life-table product limit estimates. Results: Three hundred seventy-seven men met inclusion criteria. Mean age at diagnosis was 61.9 years. Fifty-three percent of men had prostate-specific antigen of 6 ng/mL or less, and 94% had Gleason score of 6 or less. A majority of men were cT1 (62%), had less than 33% of biopsy cores involved (80%), and were low risk (77%) at diagnosis. Median number of cores taken at diagnostic biopsy was 13, mean time to follow-up was 18.5 months, and 29% of men had three or more repeat biopsies. Overall, 34% (129 men) were found to have an increase in Gleason grade. The majority of men who experienced an upgrade (81%) did so by their second repeat biopsy. Conclusion: A proportion of men experience an upgrade in Gleason score while undergoing active surveillance. Men who experience early upgrading likely represent initial sampling error, whereas later upgrading may reflect tumor dedifferentiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Active Surveillance for Prostate Cancer: A Systematic Review of the Literature
Dall’Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., Freedland, S. J., Klotz, L. H., Parker, C., & Soloway, M. S. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.072 · Cited by 602
Self-citationTosoian, J. J., Mamawala, M., Epstein, J. I., Landis, P., Macura, K. J., Simopoulos, D. N., Carter, H. B., & Gorin, M. A. (2020) · European Urology · doi:10.1016/j.eururo.2019.12.017 · Cited by 259
Blume-Jensen, P., Berman, D. M., Rimm, D. L., Shipitsin, M., Putzi, M., Nifong, T. P., Small, C., Choudhury, S., Capela, T., Coupal, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2603 · Cited by 179
“These revisions may reflect initial biopsy sampling error (13), or pathologist discordance in tumor grading (14), both of which can contribute either to overtreatment or delayed treatment of disease (4).”
Background
Metadata
- Authors
- Porten, S. P., Whitson, J. M., Cowan, J. E., Cooperberg, M. R., Shinohara, K., Perez, N., Greene, K. L., Meng, M. V., & Carroll, P. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-07-10
- Volume
- 29
- Issue
- 20
- Pages
- 2795-2800
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114709771
- Cited by
- 200
- References
- 0
- FWCI
- 18.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance. https://app.cochat.ai/papers/10.1200/jco.2010.33.0134
- The paper
- Porten, S. P., Whitson, J. M., Cowan, J. E., Cooperberg, M. R., Shinohara, K., Perez, N., Greene, K. L., Meng, M. V., & Carroll, P. R. (2011). Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.0134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.